Impact of frailty on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a nationwide cohort study.

MLA

Grymonprez, Maxim, et al. “Impact of Frailty on the Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) in Patients with Atrial Fibrillation: A Nationwide Cohort Study.” European Heart Journal. Quality of Care & Clinical Outcomes, vol. 10, no. 1, Jan. 2024, pp. 55–65. EBSCOhost, https://doi.org/10.1093/ehjqcco/qcad019.

APA

Grymonprez, M., Petrovic, M., De Backer, T. L., Steurbaut, S., & Lahousse, L. (2024). Impact of frailty on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a nationwide cohort study. European Heart Journal. Quality of Care & Clinical Outcomes, 10(1), 55–65. https://doi.org/10.1093/ehjqcco/qcad019

Chicago

Grymonprez, Maxim, Mirko Petrovic, Tine L De Backer, Stephane Steurbaut, and Lies Lahousse. 2024. “Impact of Frailty on the Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) in Patients with Atrial Fibrillation: A Nationwide Cohort Study.” European Heart Journal. Quality of Care & Clinical Outcomes 10 (1): 55–65. doi:10.1093/ehjqcco/qcad019.